Cathepsin L Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cathepsin L is a lysosomal cysteine protease encoded by the CTSL gene. It belongs to the papain family (family C1) of cysteine proteases and plays essential roles in intracellular protein degradation, antigen processing, and various physiological and pathological processes. Cathepsin L is one of the most active lysosomal proteases and is crucial for normal cellular function.
| Property |
Value |
| Protein Name |
Cathepsin L |
| Gene |
CTSL |
| UniProt ID |
P07711 |
| PDB ID |
2YJC |
| Molecular Weight |
33 kDa (proenzyme), 25 kDa (mature enzyme) |
| Subcellular Localization |
Lysosome |
| Protein Family |
Papain family (C1A) |
Cathepsin L is synthesized as a preproenzyme:
- Signal peptide: Targets the protein to the secretory pathway
- Propeptide: Inhibits activity until reaching the lysosome
- Mature enzyme: Active protease following propeptide cleavage
The mature enzyme contains:
- Active site: Catalytic cysteine (C25), histidine (H163), and asparagine (N183)
- Occluding loop: Regulates substrate access
- Two disulfide bonds: Stabilize the structure
Cathepsin L degrades proteins in lysosomes as part of normal cellular protein turnover:
- Long-lived proteins
- Misfolded proteins
- Aggregated proteins
- Generates peptides for MHC class II presentation
- Essential for proper immune surveillance
- When secreted, degrades extracellular matrix proteins
- Involved in tissue remodeling and wound healing
- Participates in autophagic flux
- Contributes to protein aggregate clearance
Cathepsin L has complex roles in AD:
- Aβ metabolism: Can degrade Aβ peptides and potentially generate amyloidogenic fragments
- Tau processing: May process tau protein in AD brain
- Upregulation: Increased in AD brain, particularly in lysosomes of affected neurons[1]
- α-synuclein clearance: Cathepsin L can degrade α-synuclein
- Lewy body formation: May be involved in processing Lewy body components
- Therapeutic potential: Enhancing cathepsin L activity may improve α-synuclein clearance[2]
- Cathepsin L deficiency causes a form of NCL
- Accumulation of lipofuscin-like material in neurons
- Synthetic inhibitors: Being developed for cancer therapy
- Specificity challenges: Cross-reactivity with other cathepsins
- Small molecule activators: Being explored for neurodegenerative diseases
- Gene therapy approaches: Increasing CTSL expression
- Autophagy enhancers: Boosting lysosomal function
Cathepsin L activity can be measured in:
- CSF: Altered levels in AD and PD
- Blood: Potential peripheral biomarker
- Brain tissue: Elevated in neurodegenerative diseases
[1] Cataldo AM, et al. (1990). Properties of the amyloid β-protein precursor degrading enzyme(s) in brain. Journal of Neurochemistry.
[2] McGowan E, et al. (2005). Alpha-synuclein and neurodegeneration. Neurochemical Research.
The study of Cathepsin L Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Platt FM, et al. "Lysosomal storage disorders." Nat Rev Dis Primers. 2024;10(1):50. PMID:38693102
- [2] Walkley SU, et al. "Lysosomal storage diseases: Pathways and therapeutic strategies." Nat Rev Neurol. 2023;19(12):715-734. PMID:37993567
- [3] Parenti G, et al. "Lysosomal storage diseases: From pathophysiology to therapy." Adv Pharmacol. 2023;97:1-30. PMID:37633281
- [4] Sun A. "Lysosomal storage disease overview." J Biochem. 2022;171(3):287-305. PMID:35040912
- [5] Wang RY, et al. "Enzyme replacement therapy for mucopolysaccharidoses." Mol Genet Metab. 2021;133(2):105-121. PMID:33865689